Key result
CRISPR-Cas emerges as an efficient tool for disease modeling, rectifying mutations, and antiviral therapies.
Why the study?
Recent advances have improved the efficiency of the CRISPR-Cas system, enabling novel variants and strategies for diverse applications.
Recent advances in the CRISPR-Cas system have improved its efficiency, enabling applications in disease modeling, mutation correction, and antiviral therapies.
May inform preclinical CRISPR applications; leaves open need for clinical validation trials.
Clustered regulatory interspaced short palindromic repeats (CRISPR) in association with CRISPR-associated protein (Cas) is an adaptive immune system, playing a pivotal role in the defense of bacteria and archaea. Ease of handling and cost effectiveness make the CRISPR-Cas system an ideal programmable nuclease tool. Recent advances in understanding the CRISPR-Cas system have tremendously improved its efficiency. For instance, it is possible to recapitulate the chronicle CRISPR-Cas from its infancy and inaugurate a developed version by generating novel variants of Cas proteins, subduing off-target effects, and optimizing of innovative strategies. In summary, the CRISPR-Cas system could be employed in a number of applications, including providing model systems, rectification of detrimental mutations, and antiviral therapies.
No takes yet. Share an insight, caveat, or question.
Bayat et al. (2017) reported a review. CRISPR-Cas system was evaluated. The CRISPR-Cas system is an ideal programmable nuclease tool with improved efficiency and potential applications in providing model systems, rectifying detrimental mutations, and antiviral therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: